circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Silver salts have antiseptic properties. In 1881 Credé introduced a method known as Credé's prophylaxis, which used of dilute (2%) solutions of silver nitrate in newborn babies' eyes at birth to prevent contraction of gonorrhea from the mother, which could cause blindness via ophthalmia neonatorum. (Modern antibiotics are now used instead). Fused silver nitrate, shaped into sticks, was traditionally called "lunar caustic". It is used as a cauterizing agent, for example to remove granulation tissue around a stoma. General Sir James Abbott noted in his journals that in India in 1827 it was infused by a British surgeon into wounds in his arm resulting from the bite of a mad dog to cauterize the wounds and prevent the onset of rabies. Silver nitrate is used to cauterize superficial blood vessels in the nose to help prevent nosebleeds. Dentists sometimes use silver nitrate-infused swabs to heal oral ulcers. Silver nitrate is used by some podiatrists to kill cells located in the nail bed. The Canadian physician C. A. Douglas Ringrose researched the use of silver nitrate for sterilization procedures, believing that silver nitrate could be used to block and corrode the fallopian tubes. The technique was ineffective.
=== Fibroblast growth factor === Platelet-derived growth factors (PDGFs) are polypeptides found in various tissues, including bone, where it was originally postulated that it could act as an autologous regulator of bone remodeling. This protein has been initially isolated in human platelets, and is composed of two different polypeptide chains A and B. The combination of these polypeptides form the homodimeric (AA) or (BB), or heterodimeric (AB) chains of PDGF. Fibroblast growth factor (FGF) signaling cascade is started by the binding of 2 growth factors to the FGFR. Dimerization takes place and initiates the transphosphorylation of each receptor. These phosphorylation sites act as docking sites for proteins so they may induce downstream signaling. These proteins consist of FRS2-alpha and PLC-gamma. FRS2-alpha acts as a scaffold protein to hold GAB1 and GRB2 which then proteins bind to SHP2 and SOS. These several proteins act together to activates the Ras pathway (induces cell proliferation and differentiation) and the PI3K pathway (induces survival and cell fate determination). On the other side of the dimerized receptors, PLC-gamma activates DAG and IP3 which yield PKC and calcium ions. PKC and calcium will ultimately induce morphology, migration, and adhesion.
The project intended to stop the flow of firearms from the United States into Mexico and deny cartels weapons considered 'tools of the trade.' In 2011, a gunwalking scandal, later known as "Operation Fast and Furious," occurred when the ATF was accused of permitting and facilitating "straw purchase" firearm sales to traffickers, and allowing the guns to "walk" and be transported to Mexico. Allegedly, the ATF allowed to complete the transactions to expose the supply chain and gather intelligence. It has been established that this operation violated long-established ATF policies and practices and that it is not a recognized investigative technique. Several of the guns sold under the Project Gunrunner were recovered from crime scenes in Arizona, and at crime scenes throughout Mexico, resulting in considerable controversy. One notable incident was the "Black Swan operation" where Joaquín Guzmán Loera was finally captured. The ATF confirmed that one of the weapons the Mexican Navy seized from Guzmán's gunmen was one of the many weapons that were "lost" during the Project Gunrunner. Researchers and Mexican officials have argued that most weapons trafficked into Mexico originate from the United States. The U.S. Department of Homeland Security (DHS) officials have stated that the statistic is misleading: out of approximately 30,000 weapons seized in drug cases in Mexico in 2004–2008, 7,200 appeared to be of U.S. origin, approximately 4,000 were found in ATF manufacturer and importer records, and 87 percent of those—3,480—originated in the United States. The U.S.
Sources: en.wikipedia.org
=== Legal status === For follicular lymphoma, the U.S. Food and Drug Administration (FDA) awarded copanlisib orphan drug designation in February 2015, and fast track designation in February 2016. The New drug application for follicular lymphoma was granted priority review in May 2017. In September 2017, it received accelerated approval for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies. Further clinical trials are to be performed as a post-marketing requirement to verify the clinical benefit. Copanlisib was granted orphan drug status for the treatment of splenic, nodal and extranodal subtypes of marginal zone lymphoma.
=== Attacks by Israel === On 25 April, the Lebanese Health Ministry reported that six people, four in Yohmor Al-Shaqeef, Nabatieh and two in Safad al-Battikh, Bint Jbeil, were killed by Israeli attacks under the orders of Israeli Prime Minister Benjamin Netanyahu to "forcefully attack Hezbollah targets" after the IDF accused the group of breaching the ceasefire agreement. On 26 April, the Lebanese Health Ministry stated that 14 people, including two women and two children, were killed and 37 others were injured by Israeli attacks in southern Lebanon. On 28 April, Israeli forces launched a double tap strike in Majdal Zoun, killing 9 people, including three emergency workers. The Israeli military stated that the strike targeted a Hezbollah commander operated in an Israeli-occupied area in southern Lebanon, despite providing no evidence. On 30 April, the National News Agency reported that several Israeli attacks targeted places in southern Lebanon, killing at least 28 people. President Joseph Aoun condemned Israel's "continuing violations", stating that "despite the ceasefire, as do demolitions of homes and places of worship, while the number of killed and wounded rises day after day". On 1 May, the Health Ministry of Lebanon reported that 13 people, including four women and a child, were killed by Israeli attacks in Habboush, Zrariyeh and Ain Baal. On 15 May, an Israeli airstrike targeted the town of Harouf, southern Lebanon, killing at least six people, including three paramedics.
== Causes == Causes of eclabium include but are not limited to General Ichthyosis. Congenital ichthyosis Lamellar ichthyosis Harlequin type Ichthyosis Scarring after trauma, such as surgery Gingivitis/periodontitis
Sources: en.wikipedia.org
Whether attempted via passive diffusion from 'mashed' gel pieces or the use of 'dissolvable' formulations, full quantitative recovery has never been demonstrated and/or there is concern that the necessary treatments can modify the resolved native proteoforms. Thus, while recovery of fully intact proteoforms from the gel would be optimal to ensure full sequence coverage, in-gel digestion is an effective option for subsequent LC/MS/MS analyses.
=== Background === Proteins are essential macromolecules of living organisms. They are continuously being degraded into their constituent amino acids which can be reused in the synthesis of new proteins. Every cellular protein has its own half-life time. In humans, for instance, 50% of the liver and plasma proteins are replaced in 10 days, whereas in muscles it takes 180 days. On average, about 50% of our proteins are replaced every 80 days. Although the regulation of protein degradation is as important as their synthesis to keep cellular protein concentrations at optimum levels, research in this area remained until the end of the 1970s. Up to this time, lysosomes, discovered in the 1950s by the Belgian cytologist Christian de Duve, were thought responsible for the complete digestion of intra- and extracellular proteins by the lysosomal hydrolytic enzymes. Between the 1970s and 1980s, this view drastically changed. New experimental evidences showed that, under physiological conditions, non-lysosomal proteases were responsible for limited proteolysis of intra- and/or extracellular proteins, a concept originally conceived by Linderstᴓm-Lang in 1950. Endogenous or exogenous proteins are processed by non-lysosomal proteases into intermediate-sized polypeptides, which display gene and metabolic regulation, neurologic, endocrine, and immunological roles, whose dysfunction might explain a number of pathologies.
As an international coalition under United States command assembled in anticipation of an invasion of Iraqi-occupied Kuwait, the Iraqi regime decided to destroy as much of Kuwait's oil reserves and infrastructure as possible before withdrawing from the country. As early as December 1990, Iraqi forces placed explosive charges on Kuwaiti oil wells. The wells were systematically sabotaged beginning on January 16, 1991, when the allies commenced air strikes against Iraqi targets. On February 8, satellite images detected the first smoke from burning oil wells. The number of oil fires peaked between February 22 and 24, when the allied ground offensive began. According to the U.S. Environmental Protection Agency's report to Congress, "the retreating Iraqi army set fire to or damaged over 700 oil wells, storage tanks, refineries, and facilities in Kuwait." Estimates placed the number of oil well fires from 605 to 732. A further thirty-four wells had been destroyed by heavy coalition bombing in January. The Kuwait Petroleum Company's estimate as of September 1991 was that there had been 610 fires, out of a total of 749 facilities damaged or on fire along with an unspecified number of oil filled low-lying areas, such as "oil lakes" and "fire trenches". These fires constituted approximately 50% of the total number of oil well fires in the history of the petroleum industry, and temporarily damaged or destroyed approximately 85% of the wells in every major Kuwaiti oil field. Concerted efforts to bring the fires and other damage under control began in April 1991.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.